The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-11-1764
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

The HDAC Inhibitor LBH589 (Panobinostat) Is an Inhibitory Modulator of Aromatase Gene Expression

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2010English

HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-Pd-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment

Journal of Cancer
Oncology
2020English

Host Histone Acetylation Unlocks HDAC Inhibitor Potential

Oncotarget
Oncology
2017English

A Novel Tankyrase Inhibitor, MSC2504877, Enhances the Effects of Clinical CDK4/6 Inhibitors

Scientific Reports
Multidisciplinary
2019English

HDAC Inhibitor LMK‑235 Promotes the Odontoblast Differentiation of Dental Pulp Cells

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2017English

Phase I Study of the mTOR Inhibitor Ridaforolimus and the HDAC Inhibitor Vorinostat in Advanced Renal Cell Carcinoma and Other Solid Tumors

Investigational New Drugs
OncologyPharmacology
2015English

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy--Response

Clinical Cancer Research
Cancer ResearchOncology
2016English

HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2 + Tumors

Cancer Research
Cancer ResearchOncology
2017English

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells

PLoS ONE
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy